Apolipoprotein e epsilon-4 polymorphism is associated with younger age at referral to a lipidology clinic and a poorer response to lipid-lowering therapy

Lipids in Health and Disease

Volumn 10, Issue , 2011, Pages

  Baptista, Rui ^a   Rebelo, Marta ^a   Decq Mota, Joana ^a   Dias, Patrícia ^a   Monteiro, Pedro ^a   Providncia, Luís A ^a   Silva, José M ^a  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; APOLIPOPROTEIN A; APOLIPOPROTEIN B; APOLIPOPROTEIN E; APOLIPOPROTEIN E EPSILON 4; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; APOLIPOPROTEIN E4;

ADULT; AGE DISTRIBUTION; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DNA EXTRACTION; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GENE DOSAGE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HOSPITAL; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; RISK FACTOR;

ADULT; APOLIPOPROTEIN E4; DYSLIPIDEMIAS; FEMALE; GENOTYPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 79953118492     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-10-48     Document Type: Article

References (35)

1. Apolipoprotein E polymorphism and atherosclerosis. J Davignon RE Gregg CF Sing, Arteriosclerosis 1988 8 1 21 3277611 (Pubitemid 18049171)
2. Apolipoprotein E polymorphism, age and coronary heart disease. GD Kolovou KK Anagnostopoulou, Ageing Res Rev 2007 6 94 108 10.1016/j.arr.2006.11.001 17224309 (Pubitemid 47017805)
3. Apolipoprotein E polymorphism in cerebrovascular & coronary heart diseases. S Anoop A Misra K Meena K Luthra, Indian J Med Res 2010 132 363 378 20966513
4. Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype. YA Kesaniemi C Ehnholm TA Miettinen, J Clin Invest 1987 80 578 581 10.1172/JCI113107 3611358
5. Apolipoprotein E: far more than a lipid transport protein. RW Mahley SC Rall Jr, Annu Rev Genomics Hum Genet 2000 1 507 537 10.1146/annurev.genom.1.1. 507 11701639
6. Apolipoprotein E polymorphism, serum lipids, myocardial infarction and severity of angiographically verified coronary artery disease in men and women. S Lehtinen T Lehtimaki T Sisto JP Salenius M Nikkila H Jokela T Koivula F Ebeling C Ehnholm, Atherosclerosis 1995 114 83 91 10.1016/0021-9150(94)05469-Y 7605379
7. The importance of plasma apolipoprotein E concentration in addition to its common polymorphism on inter-individual variation in lipid levels: results from Apo Europe. N Haddy D De Bacquer MM Chemaly M Maurice C Ehnholm A Evans S Sans M Do Carmo Martins G De Backer G Siest S Visvikis, Eur J Hum Genet 2002 10 841 850 10.1038/sj.ejhg.5200864 12461692 (Pubitemid 36054566)
8. APOE polymorphism is associated with lipid profile, but not with arterial stiffness in the general population. RO Alvim SR Freitas NE Ferreira PC Santos RS Cunha JG Mill JE Krieger AC Pereira, Lipids Health Dis 2010 9 128 10.1186/1476-511X-9-128 21059196
9. Relationship of the ApoE polymorphism to plasma lipid traits among South Asians, Chinese, and Europeans living in Canada. D Burman A Mente RA Hegele S Islam S Yusuf SS Anand, Atherosclerosis 2009 203 192 200 10.1016/j. atherosclerosis.2008.06.007 18656198
10. Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease. JE Eichner LH Kuller TJ Orchard GA Grandits LM McCallum RE Ferrell JD Neaton, Am J Cardiol 1993 71 160 165 10.1016/0002-9149(93)90732-R 8421977 (Pubitemid 23030638)
11. Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. JH Stengard KE Zerba J Pekkanen C Ehnholm A Nissinen CF Sing, Circulation 1995 91 265 269 7805227
12. Apolipoprotein E polymorphisms and age at first coronary artery bypass graft. MF Newman DT Laskowitz WD White JL Kirchner HP Grocott M Stafford-Smith MH Sketch RH Jones JG Reves AM Saunders, Anesth Analg 2001 92 824 829 10.1097/00000539-200104000-00006 11273909 (Pubitemid 32239117)
13. Association of apolipoprotein E genotypes with lipid levels and coronary risk. AM Bennet E Di Angelantonio Z Ye F Wensley A Dahlin A Ahlbom B Keavney R Collins B Wiman U de Faire J Danesh, JAMA 2007 298 1300 1311 10.1001/jama.298.11.1300 17878422 (Pubitemid 47443344)
14. APOE genotype, lipids, and coronary heart disease risk: A prospective population study. H Ward PN Mitrou R Bowman R Luben NJ Wareham KT Khaw S Bingham, Arch Intern Med 2009 169 1424 1429 10.1001/archinternmed.2009.234 19667307
15. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 106 3143 3421 12485966
16. Apolipoprotein E polymorphism and cardiovascular disease: A HuGE review. JE Eichner ST Dunn G Perveen DM Thompson KE Stewart BC Stroehla, Am J Epidemiol 2002 155 487 495 10.1093/aje/155.6.487 11882522 (Pubitemid 34208040)
17. Apolipoprotein E and familial dysbetalipoproteinemia: clinical, biochemical, and genetic aspects. AH Smelt F de Beer, Semin Vasc Med 2004 4 249 257 10.1055/s-2004-861492 15630634 (Pubitemid 40094489)
18. ApoE genotype affects allele-specific apo[a] levels for large apo[a] sizes in African Americans: the Harlem-Basset Study. E Anuurad G Lu J Rubin TA Pearson L Berglund, J Lipid Res 2007 48 693 698 10.1194/jlr.M600431-JLR200 17172560 (Pubitemid 46397472)
19. Apolipoprotein E polymorphism affects plasma levels of lipoprotein(a). P de Knijff A Kaptein D Boomsma HM Princen RR Frants LM Havekes, Atherosclerosis 1991 90 169 174 10.1016/0021-9150(91)90111-F 1836947
20. Context-dependent and invariant associations between lipids, lipoproteins, and apolipoproteins and apolipoprotein E genotype. R Frikke-Schmidt BG Nordestgaard B Agerholm-Larsen P Schnohr A Tybjaerg-Hansen, J Lipid Res 2000 41 1812 1822 11060351
21. ApoE plasma levels and risk of cardiovascular mortality in old age. SP Mooijaart JF Berbee D van Heemst LM Havekes AJ de Craen PE Slagboom PC Rensen RG Westendorp, PLoS Med 2006 3 176 10.1371/journal.pmed.0030176 16671834
22. Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study. BD Chiodini MG Franzosi S Barlera S Signorini CM Lewis A D'Orazio P Mocarelli E Nicolis R Marchioli G Tognoni, Eur Heart J 2007 28 1977 1983 10.1093/eurheartj/ehm196 17567623 (Pubitemid 47579537)
23. Apolipoprotein epsilon 4 homozygosity in young men with coronary heart disease. FM van Bockxmeer CD Mamotte, Lancet 1992 340 879 880 10.1016/0140-6736(92)93288-X 1357300
24. Apolipoprotein epsilon 4 homozygosity - a determinant of restenosis after coronary angioplasty. FM van Bockxmeer CD Mamotte FR Gibbons RR Taylor, Atherosclerosis 1994 110 195 202 10.1016/0021-9150(94)90204-6 7848369
25. Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico). Ital Heart J 2000 1 810 820 11302109
26. Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease. T Nieminen M Kahonen LE Viiri P Gronroos T Lehtimaki, Pharmacogenomics 2008 9 1475 1486 10.2217/14622416.9.10.1475 18855536
27. Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort. JF Thompson CL Hyde LS Wood SA Paciga DA Hinds DR Cox GK Hovingh JJ Kastelein, Circ Cardiovasc Genet 2009 2 173 181 10.1161/CIRCGENETICS.108.818062 20031582
28. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. CM Ballantyne JA Herd EA Stein LL Ferlic JK Dunn AM Gotto Jr AJ Marian, J Am Coll Cardiol 2000 36 1572 1578 10.1016/S0735-1097(00)00918-9 11079660
29. A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin. P Nestel L Simons P Barter P Clifton D Colquhoun I Hamilton-Craig K Sikaris D Sullivan, Atherosclerosis 1997 129 231 239 10.1016/S0021-9150(96)06031-5 9105566 (Pubitemid 27135325)
30. Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia. JP Ojala E Helve C Ehnholm K Aalto-Setala KK Kontula MJ Tikkanen, J Intern Med 1991 230 397 405 10.1111/j.1365-2796.1991. tb00464.x 1940775
31. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. JM Ordovas J Lopez-Miranda F Perez-Jimenez C Rodriguez JS Park T Cole EJ Schaefer, Atherosclerosis 1995 113 157 166 10.1016/0021-9150(94)05439-P 7605354
32. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: A Go-DARTS study. LA Donnelly CN Palmer AL Whitley CC Lang AS Doney AD Morris PT Donnan, Pharmacogenet Genomics 2008 18 279 287 10.1097/FPC.0b013e3282f60aad 18334912 (Pubitemid 351367521)
33. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: A substudy of the Scandinavian simvastatin survival study. LU Gerdes C Gerdes K Kervinen M Savolainen IC Klausen PS Hansen YA Kesaniemi O Faergeman, Circulation 2000 101 1366 1371 10736278 (Pubitemid 30169856)
34. Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia. C Sanllehy E Casals C Rodriguez-Villar D Zambon J Ojuel AM Ballesta E Ros, Metabolism 1998 47 560 565 10.1016/S0026-0495(98)90240-2 9591747 (Pubitemid 28213116)
35. Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting. R Pena C Lahoz JM Mostaza J Jimenez E Subirats X Pinto M Taboada A Lopez-Pastor, J Intern Med 2002 251 518 525 10.1046/j.1365-2796.2002. 00991.x 12028507 (Pubitemid 34535524)